KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Enterprise Value (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Enterprise Value for 13 consecutive years, with -$548.9 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 12.45% to -$548.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$548.9 million through Dec 2025, up 12.45% year-over-year, with the annual reading at -$548.9 million for FY2025, 12.45% up from the prior year.
  • Enterprise Value for Q4 2025 was -$548.9 million at Xenon Pharmaceuticals, up from -$913.0 million in the prior quarter.
  • The five-year high for Enterprise Value was -$249.6 million in Q3 2021, with the low at -$913.0 million in Q3 2025.
  • Average Enterprise Value over 5 years is -$566.3 million, with a median of -$550.7 million recorded in 2021.
  • The sharpest move saw Enterprise Value tumbled 211.74% in 2021, then soared 32.43% in 2025.
  • Over 5 years, Enterprise Value stood at -$551.8 million in 2021, then dropped by 7.31% to -$592.1 million in 2022, then decreased by 7.77% to -$638.1 million in 2023, then increased by 1.75% to -$626.9 million in 2024, then rose by 12.45% to -$548.9 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$548.9 million, -$913.0 million, and -$487.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.